Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-hepatitis D antibody refers to a therapeutic approach utilizing antibodies to target the hepatitis D virus (HDV) in patients with chronic infection. In the context of the **SAMBA-D study** (Safety and efficacy of therapeutic antibodies targeting hepatitis D virus in patients with chronic hepatitis D infection), this intervention is being evaluated in a Phase 3 clinical trial setting. The treatment aims to neutralize the virus or prevent its entry and spread within hepatocytes, addressing the severe liver disease associated with chronic HDV, which currently has limited therapeutic options. The trial is sponsored by **Region Midtjylland** (Central Denmark Region) and involves clinical sites in Germany and Denmark.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-hepatitis D antibody.